Balanced news tone
News Sentiment
NKTX sentiment intelligence
Nkarta Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
55
Balanced news tone
51 relevant articles
Price is moving more forcefully than the current news tone suggests.
79/100 classification confidence.
directly relevant articles
high-authority source matches
-7.8% over one week, +3.8% over four weeks, trend active, and near fair-value range.
Companies Like Nkarta (NASDAQ:NKTX) Are In A Position To Invest In Growth
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
79/100 classification
One-week reaction
-7.8%
Price reacting lower
Trend fit
Trend active
3.8% over four weeks
Fair value
-18.1%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
15
Neutral
33
Negative
3
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
simplywall.st
Direct company coverage
Companies Like Nkarta (NASDAQ:NKTX) Are In A Position To Invest In Growth
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 07 Jul 2026 10:19
- Source
- simplywall.st
Moomoo
Direct company coverage
Needham Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11
Needham has reiterated its Buy rating for Nkarta (NKTX.US), maintaining a target price of $11. This indicates the firm's continued confidence in the company's prospects.
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 02 Jul 2026 05:10
- Source
- Moomoo
Investing.com UK
Direct company coverage
Nkarta at H.C. Wainwright cell therapy conference: autoimmune push By Investing.com
Nkarta (NKTX) presented its allogeneic CAR NK platform for autoimmune diseases at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. The company is focusing on B-cell-driven autoimmune diseases like lupus nephritis and rheumatoid arthritis, aiming for outpatient trea
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 30 Jun 2026 18:40
- Source
- Investing.com UK
Market source
Direct company coverage
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Nkarta, Inc. announced its participation in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference. President Nadir Mahmood will present updates on the company's investigational CAR-NK cell therapy for autoimmune diseases in a fireside chat on June 30th at 2 p.m. ET. A we
- Tone
- Positive 62/100
- Event
- Regulatory and legal
- Published
- 30 Jun 2026 08:12
- Source
- Market source
TradingView
Direct company coverage
Price to sales forward of Nkarta, Inc. – NASDAQ:NKTX
This page displays the forward "Price to sales" metric for Nkarta, Inc. (NASDAQ: NKTX). The content is primarily a data placeholder, indicating the period, value, and change for this financial metric, but the actual numerical data is not provided in the extracted content.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 06:10
- Source
- TradingView
TradingView
Direct company coverage
Price to book forward of Nkarta, Inc. – NASDAQ:NKTX
The article "Price to book forward of Nkarta, Inc. – NASDAQ:NKTX" provides a snapshot of Nkarta, Inc.'s stock (NKTX) on the Nasdaq. It shows the company's financial data, specifically focusing on its price to book forward metric. The brief content indicates that the market was cl
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 19:10
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of Nkarta, Inc. – NASDAQ:NKTX
This article provides financial information for Nkarta, Inc. (NASDAQ: NKTX), specifically focusing on its enterprise value to revenue forward. It appears to be a financial data page from TradingView, offering an overview of the company's financials, news, and other related market
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Jun 2026 12:12
- Source
- TradingView
Pluang
Direct company coverage
Nkarta to present CAR-NK cell therapy updates a...
Nkarta, Inc., a clinical-stage biotech company, will present updates on its investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. President Nadir Mahmood will discuss the pro
- Tone
- Positive 74/100
- Event
- Regulatory and legal
- Published
- 28 Jun 2026 07:40
- Source
- Pluang
Stock Titan
Direct company coverage
Nkarta sets June 30 fireside chat on CAR-NK autoimmune therapy
Nkarta (Nasdaq: NKTX), a clinical-stage biopharmaceutical company, will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. President Nadir Mahmood will host a fireside chat at 2 p.m. ET to discuss the company’s investigational CAR-NK c
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 26 Jun 2026 12:39
- Source
- Stock Titan
Moomoo
Direct company coverage
TD Cowen Initiates Nkarta(NKTX.US) With Buy Rating
TD Cowen has initiated coverage on Nkarta (NKTX.US) with a Buy rating. The firm has set a price target of $10.00 for the biopharmaceutical company.
- Tone
- Positive 85/100
- Event
- Analyst action
- Published
- 24 Jun 2026 02:40
- Source
- Moomoo
Investing.com
Direct company coverage
TD Cowen initiates Nkarta stock with buy rating on NK cell therapy
TD Cowen has initiated coverage on Nkarta Inc. (NASDAQ:NKTX) with a "buy" rating, citing the potential of its lead candidate NKX019, an engineered natural killer cell therapy, to advance the standard of care in autoimmune diseases. The stock has seen a 60% surge over the past yea
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 23 Jun 2026 11:09
- Source
- Investing.com
MT Newswires
Direct company coverage
TD Cowen Initiates Nkarta at Buy
- Tone
- Positive 58/100
- Event
- Market update
- Published
- 23 Jun 2026 10:05
- Source
- MT Newswires
Stock Titan
Direct company coverage
Shares of Nkarta (NKTX) CEO Paul J. Hastings decrease by 1,776. He still owns 390,247 shares.
Nkarta, Inc. CEO Paul J. Hastings reported a sale of 1,776 common stock shares at $2.71 each, primarily to cover tax withholding obligations related to Restricted Stock Unit vesting. This transaction is considered routine and non-discretionary, as indicated in the filing. Followi
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 22 Jun 2026 19:41
- Source
- Stock Titan
MarketBeat
Direct company coverage
Nkarta (NKTX) Stock Price, News & Analysis
Nkarta, Inc. (NASDAQ: NKTX) is a clinical-stage biotechnology company developing off-the-shelf natural killer (NK) cell therapies for cancer. The stock currently trades at $2.79, with analysts giving it a "Moderate Buy" consensus rating and a price target of $10.75, representing
- Tone
- Positive 64/100
- Event
- Analyst action
- Published
- 20 Jun 2026 12:09
- Source
- MarketBeat
TradingKey
Direct company coverage
Nkarta Inc (NKTX) Institutional Confidence
Nkarta Inc (NKTX) has an institutional shareholding score of 7.00, placing it 81st out of 389 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 82.11%, which is a 4.32% decrease quarter-over-quarter. James Simons is the largest
- Tone
- Positive 65/100
- Event
- Market update
- Published
- 18 Jun 2026 23:10
- Source
- TradingKey
TradingKey
Direct company coverage
Nkarta Inc (NKTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Nkarta Inc (NKTX), highlighting its current price momentum, support and resistance levels, and signals from various technical indicators and moving averages. The stock is currently ranked 144 out of 389 in the Biotechnology & Medical
- Tone
- Positive 63/100
- Event
- Market update
- Published
- 18 Jun 2026 10:40
- Source
- TradingKey
TradingKey
Direct company coverage
Nkarta Inc (NKTX) Valuation: PE, PB & Fair Value Analysis
Nkarta Inc (NKTX) currently has a valuation score of 8.53, placing it 115th out of 389 companies in the Biotechnology & Medical Research industry. The company's current P/E ratio is -2.12, which is significantly below its recent high and above its recent low. However, relevant da
- Tone
- Positive 62/100
- Event
- Market update
- Published
- 18 Jun 2026 10:40
- Source
- TradingKey
TradingKey
Direct company coverage
Nkarta Inc (NKTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a brief overview of Nkarta Inc.'s (NKTX) revenue breakdown. It states that relevant data for business segments and regional revenue and profit contribution for fiscal years 2018, 2019, and 2020 have not yet been disclosed by the company. The only specific da
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 Jun 2026 23:09
- Source
- TradingKey
TradingKey
Direct company coverage
Nkarta Inc (NKTX) Financial Health: Profitability & Balance Sheet Analysis
This article provides an analysis of Nkarta Inc's (NKTX) financial health, ranking it 355 out of 388 in the Biotechnology & Medical Research industry with a weak financial status and low operating efficiency. The report details the company's scores across various financial dimens
- Tone
- Negative 30/100
- Event
- Market update
- Published
- 17 Jun 2026 22:09
- Source
- TradingKey
TradingKey
Direct company coverage
Nkarta Inc (NKTX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Nkarta Inc (NKTX), listing its major shareholders and their respective proportions as of recent updates. It breaks down shareholder types, institutional holdings over several quarters, and recent shareholder activity with changes
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 17 Jun 2026 19:41
- Source
- TradingKey
TradingKey
Direct company coverage
Nkarta Inc (NKTX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article from TradingKey provides a dividend and stock split history for Nkarta Inc (NKTX). It indicates that Nkarta Inc has not distributed any dividends over the past five years and shows no record of stock splits. The report emphasizes the absence of both dividend and stoc
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 17 Jun 2026 19:41
- Source
- TradingKey
TradingKey
Direct company coverage
Nkarta Inc (NKTX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Nkarta Inc (NKTX) has an earnings forecast score of 9.00, placing it 14th out of 388 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $11.00 for NKTX, with a "Strong Buy" rating from 4 analysts, indicating a significant upside potenti
- Tone
- Positive 72/100
- Event
- Earnings
- Published
- 17 Jun 2026 09:41
- Source
- TradingKey
The Globe and Mail
Direct company coverage
Nkarta Shareholders Back Directors, Auditor and Annual Say-on-Pay
Nkarta (NKTX) shareholders recently re-elected directors Ali Behbahani and Zachary Scheiner, ratified Ernst & Young LLP as their independent auditor, and approved executive compensation. They also expressed a preference for annual say-on-pay votes, which the board has adopted. Ti
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jun 2026 23:41
- Source
- The Globe and Mail
Stock Titan
Direct company coverage
Nkarta (NASDAQ: NKTX) reports 37,000-share option grant tied to RA Capital
Nkarta, Inc. (NASDAQ: NKTX) has reported a Form 4 detailing a compensation-related stock option grant of 37,000 shares of common stock at an exercise price of $2.46. This grant is tied to RA Capital-affiliated entities, with Dr. Scheiner holding the option for the benefit of RA C
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2026 10:09
- Source
- Stock Titan
Stock Titan
Direct company coverage
Nkarta (NKTX) investors approve directors, auditor and annual say-on-pay
Nkarta, Inc. held its 2026 annual meeting where shareholders elected two Class III directors, Ali Behbahani and Zachary Scheiner, and ratified Ernst & Young LLP as the independent auditor for the year ending December 31, 2026. Stockholders also approved, on an advisory basis, the
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 21:11
- Source
- Stock Titan
Stock Titan
Direct company coverage
Nkarta (NKTX) director receives stock options on 37,000 common shares
Nkarta, Inc. director George Vratsanos was granted stock options for 37,000 shares of common stock at an exercise price of $2.46 per share. This compensation-related award vests 100% on the earlier of June 10, 2027, or the day before the first annual stockholder meeting following
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 20:11
- Source
- Stock Titan
Stock Titan
Direct company coverage
Nkarta (NKTX) director George Simeon awarded 37,000-share stock option grant
Nkarta, Inc. director George Simeon was granted a stock option for 37,000 shares of common stock with an exercise price of $2.4600 per share, expiring on June 9, 2036. The option vests 100% on the earlier of June 10, 2027, or the day before the first annual stockholders' meeting
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 20:11
- Source
- Stock Titan
Stock Titan
Direct company coverage
Nkarta (NKTX) director awarded 37,000 stock options vesting in 2027
Nkarta, Inc. director Ali Behbahani has been granted 37,000 stock options with an exercise price of $2.46 per share and an expiration date of June 9, 2036. These options are set to fully vest on the earlier of June 10, 2027, or the day before the first annual stockholder meeting
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 20:11
- Source
- Stock Titan
Stock Titan
Direct company coverage
Nkarta (NKTX) director granted 37,000 stock options for RA Capital funds
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Jun 2026 07:00
- Source
- Stock Titan